Status: Recruiting
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 5, 2026Locations: 1
Eligibility criteria
Subjects must be willing and able to provide informed consent, undergo and compl... [+32]
Histology other than GBM, gliosarcoma, IDH wild-type astrocytoma grade III or ID... [+23]